The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The MM Hub is delighted to be reporting from the 59th American Society of Hematology (ASH) Annual Meeting held in Atlanta, Georgia, from 9-12 December 2017. On Sunday, 10 December 2017, an oral abstract session was held and entitled: Session: 653. Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance. During this session, an oral abstract was presented by Andrew Branagan from The Cancer Center, Massachusetts General Hospital, Boston, MA. The title of the talk (Abstract 438) was: Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders.
Dr. Branagan began his talk by explaining how patients with plasma cell disorders (PCDs) are highly prone to infections and that this is a major cause of morbidity, despite preventative measures such as seasonal vaccines. In order to improve immunity in these patients, Branagan and colleagues have trialed several strategies such as increasing the influenza vaccine to a two-dose series, along with higher antigen doses. In order to effectively document the effects of such a strategy, the serologic readout in PCD patients was followed over a single flu season.
Data is given as Two doses of High-Dose vaccine vs SOC plus placebo:
Dr. Branagan concluded his talk by emphasizing that a two-dose flu vaccination separated by 30 days is well tolerated and associated with high rates of seroprotection and seroconversion. Serial measurement of antibody titers for the first time in PCD patients reveal rapid and significant loss of protection during one flu season. The use of two high-dose vaccinations drives more durable responses in PCD patients and should be considered as part of the SOC regimens for these patients. Subgroups of patients were identified based on the likelihood of serologic response, with a lower likelihood for; older age, male sex, disease remission status worse than partial response (PR), increased prior lines of therapy and active alkylating agent chemotherapy. A higher likelihood was linked to higher IVIG therapy and IMiD therapy. Dr. Branagan concluded that additional studies are required in patients with PCDs with clinical endpoints. Studies are continuing in his lab with regards to further understanding the timing, kinetics and optimal doses of the vaccine required, with possible knock-on effects for other vaccines in immunologically challenged patients.
References